<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064414</url>
  </required_header>
  <id_info>
    <org_study_id>CR017008</org_study_id>
    <secondary_id>28431754DIA3004</secondary_id>
    <nct_id>NCT01064414</nct_id>
  </id_info>
  <brief_title>An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of 2 different doses of
      canagliflozin compared with placebo in patients with type 2 diabetes mellitus who have
      reduced kidney function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study drug assigned by chance), double blind (neither the patient or
      the study doctor will know the name of the assigned treatment), parallel-group, 3-arm
      (patients will be assigned to 1 of 3 treatment groups) multicenter study to determine the
      efficacy, safety, and tolerability of 2 different doses of canagliflozin (100 mg and 300 mg)
      compared to placebo (a pill that looks like all the other treatments but has no real
      medicine) in patients with type 2 diabetes mellitus (T2DM) who have renal impairment (reduced
      kidney function) and who are not achieving an adequate response from current therapy to
      control their diabetes. Canagliflozin (also referred to as JNJ-28431754) is a drug that is
      being tested to see if it may be useful in treating patients diagnosed with T2DM.
      Approximately 240 patients will participate in the study for approximately 63 to 72 weeks,
      depending on the length of the pretreatment phase. The study will consist of a pretreatment
      phase, a 52 week double blind treatment phase, and a posttreatment phase. During the
      pretreatment phase, screening evaluations will be performed to see if patients meet the entry
      criteria for the study. In addition, routine clinical procedures will be performed (physical
      examination, vital signs measurements, and an electrocardiogram [ECG]), a blood and urine
      sample will be collected for routine clinical laboratory tests, and all antihyperglycemic
      therapy taken by patients will be reviewed. Patients who meet entrance criteria for the study
      and who currently take a stable antihyperglycemic agent (AHA) regimen according to the local
      prescribing information will be eligible for inclusion in the study. Patients who meet
      entrance criteria for the study but who are not taking a stable AHA regimen according to the
      local prescribing information will enter an AHA adjustment period that may last for up to 12
      weeks. Patients will receive once daily treatment with study drug in addition to their
      current stable diabetes regimen (eg, diet, exercise, and medication therapy). Patients will
      continue to take their assigned treatment for 52 weeks (includes a 26-week core double-blind
      treatment period and a 26-week extension double-blind treatment period). During the study, if
      a patient's blood sugar remains high despite treatment with study drug in combination with
      their other antidiabetic agents, the study physician will modify the patient's treatment. If
      patients take insulin and experience low blood sugar (hypoglycemia), the dose of insulin may
      be modified. During the study, patients will be monitored for safety by review of adverse
      events, results from safety laboratory tests (including chemistry, hematology, and
      urinalysis), ECGs, vital signs measurements, body weight, physical examinations,
      self-monitored blood glucose, and collection of potential hypoglycemic episodes reported by
      patients on diary cards. The safety of patients in this study will also be monitored by a
      company internal Medical Safety Review Committee (MSRC). An Independent Data Monitoring
      Committee (IDMC) will evaluate cardiovascular (CV) events that are reported across the entire
      clinical development program for canagliflozin. Patients who complete the Week 52 visit or
      who discontinue treatment early and are withdrawn from the study will have end-of-study
      evaluations performed and a follow-up telephone interview conducted by study personnel
      approximately 30 days (but no more than 42 days) after the last dose of study drug to collect
      any serious adverse events that occurred since their last study visit. The primary outcome
      measures in the study are to assess the effect of canagliflozin relative to placebo on
      hemoglobin A1c (HbA1c, a blood test used to measure the control of diabetes) after 26 weeks
      of treatment and to assess the safety and tolerability of canagliflozin from time of signed
      informed consent to study end (includes up to 30 days following the last dose of study drug).
      All patients will take a single-blind placebo capsule once daily for 2 weeks before
      randomization to double-blind study drug. After randomization, patients will take one capsule
      of canagliflozin (either 100 mg or 300 mg) or matching placebo orally (by mouth) with liquid
      once daily for 52 weeks before the first meal each day except on days when fasting or
      pharmacokinetic blood samples are collected in which case study drug will be taken after the
      visit immediately before the patient's next meal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;7% at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 100 mg of canagliflozin once daily for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 300 mg of canagliflozin once daily for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each patient will receive matching placebo once daily for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin</intervention_name>
    <description>One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information</description>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with T2DM not on an AHA or on any AHA in monotherapy or combination therapy
             (including oral or non oral agents)

          -  Patients with reduced kidney function

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy

          -  Have proliferative diabetic retinopathy for which treatment is planned during the
             course of the study

          -  Kidney disease that required treatment with immunosuppressive therapy, history of
             dialysis or kidney transplant, presence of nephrotic syndrome (eg, severe proteinuria
             with hypoalbuminemia and/or edema), or inflammatory kidney disease

          -  Receiving anti hypertensive or anti-hyperlipidemic therapy not on a stable regimen

          -  History of a severe hypoglycemic episode within 6 months before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canal Fulton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meridian</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gosford</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reservoir</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antigonish</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Rochelle Cedex 1 Poitou-Cha</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Creusot</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Venissieux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dormagen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Einbeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schkeuditz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurangabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seognam-Si, Kyungki-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogre</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jalan Cheras N/A</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kajang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur N/A</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pulau Pinang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Culiacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morelia</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunedin Nz</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nz</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lask</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targoviste</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostov-On-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parow, Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Real</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Sebastian De Los Reyes</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <results_first_submitted>April 2, 2013</results_first_submitted>
  <results_first_submitted_qc>April 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2013</results_first_posted>
  <disposition_first_submitted>June 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 24, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2012</disposition_first_posted>
  <last_update_submitted>August 2, 2013</last_update_submitted>
  <last_update_submitted_qc>August 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Canagliflozin</keyword>
  <keyword>JNJ 28431754</keyword>
  <keyword>Placebo</keyword>
  <keyword>Sodium-Glucose Transporter 2</keyword>
  <keyword>hemoglobin A1c protein, Blood Glucose</keyword>
  <keyword>reduced kidney function, Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study evaluated the efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus and moderate renal impairment. The study was conducted between 02 March 2010 and 19 January 2012 and recruited patients from 89 study centers located in 19 countries worldwide.</recruitment_details>
      <pre_assignment_details>272 patients were randomly allocated to the 3 treatment arms. 269 patients received at least 1 dose of study drug and were included in the modified intent-to-treat (mITT) analysis set and safety analysis set. Participant flow is presented in two parts: for Baseline to Week 26 as &quot;Core Period&quot;, and for Week 26 to Week 52 as &quot;Extension Period&quot;.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Each patient received matching placebo once daily for 52 weeks. Data are presented for Baseline to Week 26 (Core Period) and for Week 26 to 52 (Extension Period).</description>
        </group>
        <group group_id="P2">
          <title>Canagliflozin 100 mg</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks. Data are presented for Baseline to Week 26 (Core Period) and for Week 26 to 52 (Extension Period).</description>
        </group>
        <group group_id="P3">
          <title>Canagliflozin 300 mg</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks.Data are presented for Baseline to Week 26 (Core Period) and for Week 26 to 52 (Extension Period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Period: Baseline to Week 26</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Period: Week 26 to Week 52</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76">1 pt completed core but did not enter ext. Reason: other (not specified).</participants>
                <participants group_id="P2" count="72">3 pts completed core but did not enter ext. Reason: other (not specified) (3).</participants>
                <participants group_id="P3" count="81">1 pt completed core but did not enter ext. Reason: other (not specified).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Each patient received matching placebo once daily for 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Canagliflozin 100 mg</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Canagliflozin 300 mg</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="89"/>
            <count group_id="B4" value="269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.2" spread="8.4"/>
                    <measurement group_id="B2" value="69.5" spread="8.2"/>
                    <measurement group_id="B3" value="67.9" spread="8.24"/>
                    <measurement group_id="B4" value="68.5" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>AUSTRALIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BELGIUM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRAZIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CANADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRANCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GERMANY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITALY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LATVIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAYSIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MEXICO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEW ZEALAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROMANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUSSIAN FEDERATION</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOUTH AFRICA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOUTH KOREA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPAIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received canagliflozin 100 mg once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received canagliflozin 300 mg once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.090"/>
                    <measurement group_id="O2" value="-0.33" spread="0.090"/>
                    <measurement group_id="O3" value="-0.44" spread="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.117</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.529</ci_lower_limit>
            <ci_upper_limit>-0.066</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.117</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.635</ci_lower_limit>
            <ci_upper_limit>-0.174</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;7% at Week 26</title>
        <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received canagliflozin 100 mg once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received canagliflozin 300 mg once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;7% at Week 26</title>
          <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>3.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>6.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received canagliflozin 100 mg once daily for 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received canagliflozin 300 mg once daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="5.089"/>
                    <measurement group_id="O2" value="-14.9" spread="5.089"/>
                    <measurement group_id="O3" value="-11.7" spread="5.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-15.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.638</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.45</ci_lower_limit>
            <ci_upper_limit>-2.307</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-12.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.683</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.36</ci_lower_limit>
            <ci_upper_limit>0.962</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected for the duration of study (52 weeks).</time_frame>
      <desc>The total number of adverse events listed in the &quot;Other (non-Serious) Adverse Events&quot; table is based upon a cut-off of greater than or equal to 5 percent of patients experiencing the adverse event in any treatment arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo: Baseline to Week 26</title>
          <description>Each patient received matching placebo once daily for 52 weeks. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E2">
          <title>Canagliflozin 100 mg: Baseline to Week 26</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E3">
          <title>Canagliflozin 300 mg: Baseline to Week 26</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E4">
          <title>Placebo: Baseline to Week 52</title>
          <description>Each patient received matching placebo once daily for 52 weeks. Data are presented for Baseline to Week 52.</description>
        </group>
        <group group_id="E5">
          <title>Canagliflozin 100 mg: Baseline to Week 52</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks. Data are presented for Baseline to Week 52.</description>
        </group>
        <group group_id="E6">
          <title>Canagliflozin 300 mg: Baseline to Week 52</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks. Data are presented for Baseline to Week 52.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 14.1 / 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Atrial fibrilation</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52. In the Week 26 study report, this event was coded as &quot;campylobacter intestinal infection&quot;; it was subsequently re-coded in the Week 52 study report as &quot;campylobacter gastroenteritis&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52. In the Week 26 study report, this event was coded as &quot;campylobacter intestinal infection&quot;; it was subsequently re-coded in the Week 52 study report as &quot;campylobacter gastroenteritis&quot;.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Diabetic complications</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Neophrolithiasis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteritis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.1 / 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52. Events for 2 patients in the placebo group in the Week 26 study report were reassessed as &quot;chronic bronchitis&quot; in the Week 52 study report.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52. In the Week 26 study report, 1 patient (placebo) had vitamin D deficiency recorded in error by the investigator which was corrected in the Week 52 study report.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Franchise Medical Leader, Cardiovascular &amp; Metabolism Franchise</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>1-800-526-7736</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

